Today, we will see why Iovance Biotherapeutics (IOVA) is one of the most attractive clinical-stage oncology picks in March 2020.
Company summary
Iovance Biotherapeutics is a clinical-stage cell therapy company focused on addressing the huge unmet demand in solid tumor space. The company is leveraging a unique mechanism of action of TILs (tumor-infiltrating lymphocytes) to develop highly personalized immune-oncology therapies. The company's lead assets, Lifileucel and LN-145, are currently being studied in pivotal trials in melanoma and cervical cancer indications, respectively. Iovance is also enrolling patients in Phase 2 trial evaluating LN-145 in